Moolec Science (MLEC) EBIT Margin (2023 - 2024)
Moolec Science's (MLEC) quarterly EBIT Margin came in at 77.92% in Q4 2024, up 63328.0% year-on-year from N/an in Q1 2024, and up 42.26% quarter-over-quarter from 134.97% in Q3 2024.
Moolec Science (MLEC) EBIT Margin (2023 - 2024) Analysis & Trends
Moolec Science has disclosed EBIT Margin across 2 years of filings, most recently posting 77.92% for Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | Moolec Science | 6.98 Bn | 6.98 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -77.92% |
| Sep 30, 2024 | -134.97% |
| Mar 31, 2024 | -96.78% |
| Dec 31, 2023 | -711.20% |
| Sep 30, 2023 | -130.34% |